Eubulus Biotherapeutics Inc. has identified molecular glue degraders acting as cyclin-dependent kinase 2 (CDK2) degradation inducers reported to be useful for the treatment of cancer.

1cbio Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

University of Notre Dame du Lac has disclosed peptide-drug conjugates, their hydrogels and their self-assembling nanofibers comprising glucagon-like peptide 1 receptor (GLP-1R) and/or gastric inhibitory polypeptide receptor (GIPR) and/or glucagon receptor agonists linked to an amphiphile moiety through a hydrophobic or hydrophilic-comprising linker acting as vaccine adjuvants reported to be useful for the treatment of diabetes and obesity.

Tuojie Biotech (Shanghai) Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of neurological disorders, cardiovascular disorders, obesity, diabetes, chronic kidney diseases and diabetic nephropathy.

Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have divulged sphingosine 1-phosphate S1P3 receptor antagonists reported to be useful for the treatment of cancer, liver diseases, neurodegeneration, and metabolic, endocrine, cardiovascular and respiratory disorders.

Haisco Pharmaceutical Group Co. Ltd. has identified pyridone derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.

China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has synthesized tricyclic heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Scientists at Gwangju Institute of Science & Technology and JD Bioscience Inc. have disclosed 5-HT2A receptor antagonists reported to be useful for the treatment of cancer, hyperlipidemia, obesity, diabetes, arteriosclerosis, hepatic steatosis, fibrosis and hypertension.

Fudan University has described dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of bone disorders, immunological disorders, inflammatory disorders, viral infections and cancer.

Shanghai Yidi Biotechnology Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes.